Prospera Private Wealth LLC Invests $35,000 in Celcuity Inc. (NASDAQ:CELC)

Prospera Private Wealth LLC bought a new stake in shares of Celcuity Inc. (NASDAQ:CELC) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 2,350 shares of the company’s stock, valued at approximately $35,000.

Several other hedge funds and other institutional investors have also made changes to their positions in CELC. Samlyn Capital LLC raised its position in Celcuity by 92.4% in the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after purchasing an additional 637,190 shares during the period. Driehaus Capital Management LLC raised its holdings in shares of Celcuity by 62.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock valued at $3,351,000 after buying an additional 78,525 shares during the period. Blue Owl Capital Holdings LP acquired a new position in Celcuity during the 2nd quarter worth approximately $1,065,000. Hennion & Walsh Asset Management Inc. purchased a new position in Celcuity in the 2nd quarter worth approximately $888,000. Finally, Point72 Asset Management L.P. acquired a new stake in Celcuity in the second quarter valued at approximately $951,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CELC. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Celcuity in a research report on Friday, November 15th. Stifel Nicolaus boosted their price objective on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Lifesci Capital started coverage on shares of Celcuity in a research report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Celcuity in a research report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Celcuity currently has an average rating of “Buy” and an average target price of $29.17.

Celcuity Stock Performance

Shares of Celcuity stock opened at $13.19 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. Celcuity Inc. has a 1 year low of $11.51 and a 1 year high of $22.19. The firm’s 50-day simple moving average is $14.93 and its 200-day simple moving average is $15.92. The firm has a market cap of $489.74 million, a PE ratio of -4.89 and a beta of 0.76.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.